gefitinib has been researched along with butyric acid in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (butyric acid) | Trials (butyric acid) | Recent Studies (post-2010) (butyric acid) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 3,556 | 85 | 1,448 |
| Protein | Taxonomy | gefitinib (IC50) | butyric acid (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, M; Hara, M; Ito, Y; Kanemitsu, Y; Kondo, E; Nakanishi, H; Nakata, S; Tanaka, H; Yatabe, Y | 1 |
1 other study(ies) available for gefitinib and butyric acid
| Article | Year |
|---|---|
Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Topics: Animals; Antineoplastic Agents; Butyric Acid; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2014 |